Opinion|Videos|December 13, 2024
Role of Step-Up Dosing
Panelists discuss how this patient was admitted after the day 1 dose of talquetamab for observation for CRS and ICANS. Patients such as this are given a 0.01-mg/kg dose on the first day, a 0.06-mg/kg dose on day 3, and a 0.04-mg/kg dose on day 5 if there are no issues. The patient is then monitored for 48 hours and is discharged before getting the 0.08-mg/kg dose.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you describe the dosing regimen for talquetamab, both as an inpatient and outpatient?
- Please highlight why we decreased dosing frequency and what the data are telling us to do now?
- Given the toxicity associated with talquetamab, can you describe the conversations with the patients when giving the first dose of talquetamab?
Advertisement
Related to this article
William A. Hall, MD, explains how fewer visits, no concurrent chemotherapy, and adaptive MRI guidance may have preserved quality of life with SBRT.
“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.
Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across various treatment settings.
Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue following the withdrawal.
Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.
William A. Hall, MD, discussed how preoperative SBRT may serve as a platform for novel systemic therapies in pancreatic adenocarcinoma.
At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence after SBRT.
Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.
Advertisement
Advertisement
Trending on CancerNetwork
1
Where Does Intensity-Modulated Proton Therapy Fit in Prostate Cancer?
2
FDA Discussion Prompts Voluntary Withdrawal of BLA for I-DXd in ES-SCLC
3
SBRT Matches Disease Control of Prostatectomy in Localized Prostate Cancer
4
Early Clinical Data Show KRAS Inhibitors Can Work in Cholangiocarcinoma
5